654 related articles for article (PubMed ID: 15022282)
21. [Epstein-Barr virus (Herpesviridae:
Smirnova KV; Lubenskaya AK; Senyuta NB; Dushenkina TE; Gurtsevitch VE
Vopr Virusol; 2023 Sep; 68(4):291-301. PubMed ID: 38156586
[TBL] [Abstract][Full Text] [Related]
22. IgA/VCA as a follow-up marker in the monitoring of nasopharyngeal carcinoma.
Sam CK; Abu-Samah AJ; Prasad U
Eur J Surg Oncol; 1994 Oct; 20(5):561-4. PubMed ID: 7926060
[TBL] [Abstract][Full Text] [Related]
23. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
Clin Vaccine Immunol; 2009 May; 16(5):706-11. PubMed ID: 19321695
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.
Henle G; Henle W
Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020
[TBL] [Abstract][Full Text] [Related]
25. Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan.
Tamada A; Makimoto K; Yamabe H; Imai J; Hinuma Y; Oyagi A; Araki T
Cancer; 1984 Feb; 53(3):430-40. PubMed ID: 6318948
[TBL] [Abstract][Full Text] [Related]
26. Altered humoral immunity against cytomegalovirus and Epstein-Barr virus without detectable virus antigens and virus-DNA in the glomeruli of patients with IGA nephropathy in remission phase.
Nagy J; Haikin H; Sarov B; Háber A; Kun L; Sarov I
Acta Microbiol Immunol Hung; 1995; 42(2):179-87. PubMed ID: 7551711
[TBL] [Abstract][Full Text] [Related]
27. The interaction and mediation effects between the host genetic factors and Epstein-Barr virus VCA-IgA in the risk of nasopharyngeal carcinoma.
Diao H; Xue WQ; Wang TM; Yang DW; Deng CM; Li DH; Zhang WL; Liao Y; Wu YX; Chen XY; Zhou T; Li XZ; Zhang PF; Zheng XH; Zhang SD; Hu YZ; Cao SM; Liu Q; Ye WM; He YQ; Jia WH
J Med Virol; 2023 Nov; 95(11):e29224. PubMed ID: 37970759
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.
Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Fachiroh J; Paramita DK; Tan IB; Haryana SM; Middeldorp JM
J Clin Microbiol; 2005 Jul; 43(7):3066-73. PubMed ID: 16002393
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus antibodies in patients with ataxia-telangiectasia and other immunodeficiency diseases.
Joncas JH; Wills A; Reece E; Fox Z
Can Med Assoc J; 1981 Oct; 125(8):845-9. PubMed ID: 6272957
[TBL] [Abstract][Full Text] [Related]
30. Enzyme-linked immunosorbent assay for antibodies to Epstein-Barr virus-associated early antigens and the viral capsid antigen.
Dölken G; Boldt C; Lange W; Weitzmann U; Löhr GW; Rosén A
Cancer Detect Prev; 1983; 6(1-2):287-92. PubMed ID: 6309387
[TBL] [Abstract][Full Text] [Related]
31. Histological types of nasopharyngeal carcinoma as compared to EBV serology.
Krueger GR; Kottaridis SD; Wolf H; Ablashi DV; Sesterhenn K; Bertram G
Anticancer Res; 1981; 1(4):187-94. PubMed ID: 6285799
[TBL] [Abstract][Full Text] [Related]
32. The Chinese epidemiological approach of nasopharyngeal carcinoma research and control.
De-Thé G
Yale J Biol Med; 1981; 54(1):33-9. PubMed ID: 6264696
[TBL] [Abstract][Full Text] [Related]
33. [The clinical usefulness of the serological study of IgG antibodies and IgA against the antigens associated with the Epstein-Barr virus in patients with nasopharyngeal carcinoma].
Amador García JM; Mendoza Montero J; Expósito Hernández J; Salinero Hernández J; Esquivias López-Cuerpo J; Ballesteros García P
Acta Otorrinolaringol Esp; 1992; 43(1):31-6. PubMed ID: 1316136
[TBL] [Abstract][Full Text] [Related]
34. Frequent association of Epstein-Barr virus in Japanese patients with Burkitt's lymphoma.
Okano M; Kikuta H; Abo W; Koizumi S; Aya T; Yano S; Takada K; Mizuno F; Osato T
Jpn J Clin Oncol; 1992 Oct; 22(5):320-4. PubMed ID: 1281896
[TBL] [Abstract][Full Text] [Related]
35. Malaria antibody levels in patients with nasopharyngeal carcinoma.
Yadav M; Prasad U
Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462
[TBL] [Abstract][Full Text] [Related]
36. Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.
Tedeschi R; Pin E; Martorelli D; Bidoli E; Marus A; Pratesi C; Bortolin MT; Zanussi S; Vaccher E; Dolcetti R; De Paoli P
Clin Vaccine Immunol; 2007 Apr; 14(4):435-41. PubMed ID: 17329446
[TBL] [Abstract][Full Text] [Related]
37. Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China.
Zeng Y; Zhong JM; Li LY; Wang PZ; Tang H; Ma YR; Zhu JS; Pan WJ; Liu YX; Wei ZN
Intervirology; 1983; 20(4):190-4. PubMed ID: 6317603
[TBL] [Abstract][Full Text] [Related]
38. Abnormal anti-Epstein Barr virus antibodies in carriers of the X-linked lymphoproliferative syndrome and in females at risk.
Sakamoto K; Seeley JK; Lindsten T; Sexton J; Yetz J; Ballow M; Purtilo DT
J Immunol; 1982 Feb; 128(2):904-7. PubMed ID: 6274962
[TBL] [Abstract][Full Text] [Related]
39. Herbal medicine use, Epstein-Barr virus, and risk of nasopharyngeal carcinoma.
Hildesheim A; West S; DeVeyra E; De Guzman MF; Jurado A; Jones C; Imai J; Hinuma Y
Cancer Res; 1992 Jun; 52(11):3048-51. PubMed ID: 1317256
[TBL] [Abstract][Full Text] [Related]
40. Immunological disorder against the Epstein-Barr virus infection and prognosis in patients with cervical carcinoma.
Kitano Y; Fujisaki S; Nakamura N; Miyazaki K; Katsuki T; Okamura H
Gynecol Oncol; 1995 May; 57(2):150-7. PubMed ID: 7537239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
